Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 1.00 |
| ▸ | FFAR1 | O14842 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.59 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5920648 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17786 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7990074 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL525378 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL524846 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL338215 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7309478 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL123324 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL4424351 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6242099 | 1.00 | GPR84 (1.00) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549985-B2 | Compositions comprising polymers prepared from 2-hydroxyalkyl acids | UNIVERSITE DE GENEVE (CH) | 2017-01-24 | — | — | US | claimed |
| EP-2598553-B1 | COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS | UNIV GENEVE (CH) | 2016-04-27 | — | — | EP | claimed |
| US-20130131190-A1 | COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS | UNIVERSITE DE GENEVE (CH) | 2013-05-23 | — | — | US | claimed |
| EP-0130288-B1 | MICROBIOLOGICALLY PREPARED D-2-HYDROXY-4-METHYLPENTANOIC-ACID DEHYDROGENASE, PROCESS FOR ITS PRODUCTION AND ITS USE | Degussa Aktiengesellschaft (DE) | 1988-03-02 | — | — | EP | claimed |
| US-4609623-A | LACTOBACILLUS OR LEUCONOSTOC | DEGUSSA AG (DE) | 1986-09-02 | — | — | US | claimed |
| JP-3197438-A | — | — | None | — | — | JP | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025101867-A1 | CELL-IMPERMEABLE AKT INHIBITORS AND PDPK1 INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-3335140-B1 | SYSTEMS, APPARATUS, AND METHODS FOR ANALYZING AND PREDICTING CELLULAR PATHWAYS | MASSACHUSETTS INST TECHNOLOGY (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117084953-A | Hair care or hair cleaning composition or skin care or skin cleaning composition | 魏德曼控股股份公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116919865-A | Dry mixture | 魏德曼控股股份公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
| US-5504107-A | ANTICOAGULANTS, PREVENTING ATHEROSCLEROSIS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0685469-A1 | PF1022 DERIVATIVE, CYCLIC DEPSIPEPTIDE | MEIJI SEIKA KAISHA LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
| WO-1995032194-A1 | SYNTHESIS OF OPTICALLY PURE 4-ALKENYL- OR 4-ALKANYL-2-HYDROXYTETRONIC ACIDS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-30 | — | — | WO | disclosed |
| EP-0666268-A1 | NOVEL SHINGOGLYCOLIPID AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5223633-A | Deprotonating a carbamate; chelation with diamine; removal of protecting group | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-29 | — | — | US | disclosed |
| JP-H03197438-A | OPTICALLY ACTIVE 1-METHYL-2-FLUOROALKYL DERIVATIVE AND LIQUID CRYSTAL COMPOSITION | KANTO CHEM CO INC | 1991-08-28 | — | — | JP | disclosed |
| US-4609623-A | LACTOBACILLUS OR LEUCONOSTOC | DEGUSSA AG (DE) | 1986-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131190-A1 | COMPOSITIONS COMPRISING POLYMERS PREPARED FROM 2-HYDROXYALKYL ACIDS | HACL2, CRYAA, HDHD5 | GPR84 4129/4885FFAR1 2013/4885MAPT 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.